

Liwei Wang

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/465636/publications.pdf>

Version: 2024-02-01

72
papers

3,620
citations

257450

24
h-index

138484

58
g-index

72
all docs

72
docs citations

72
times ranked

6206
citing authors

#	ARTICLE	IF	CITATIONS
1	Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Apatinib in Patients With Chemotherapy-Refractory Advanced or Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction. <i>Journal of Clinical Oncology</i> , 2016, 34, 1448-1454.	1.6	756
2	Regorafenib plus best supportive care versus placebo plus best supportive care in Asian patients with previously treated metastatic colorectal cancer (CONCUR): a randomised, double-blind, placebo-controlled, phase 3 trial. <i>Lancet Oncology</i> , The, 2015, 16, 619-629.	10.7	574
3	Mitochondria-Translocated PGK1 Functions as a Protein Kinase to Coordinate Glycolysis and the TCA Cycle in Tumorigenesis. <i>Molecular Cell</i> , 2016, 61, 705-719.	9.7	319
4	Efficacy and Tolerability of First-Line Cetuximab Plus Leucovorin, Fluorouracil, and Oxaliplatin (FOLFOX-4) Versus FOLFOX-4 in Patients With <i>c-RAS</i> Wild-Type Metastatic Colorectal Cancer: The Open-Label, Randomized, Phase III TAILOR Trial. <i>Journal of Clinical Oncology</i> , 2018, 36, 3031-3039.	1.6	159
5	Elevated expression level of long noncoding RNA MALAT-1 facilitates cell growth, migration and invasion in pancreatic cancer. <i>Oncology Reports</i> , 2014, 32, 2485-2492.	2.6	152
6	Long Noncoding RNA MALAT-1 Enhances Stem Cell-Like Phenotypes in Pancreatic Cancer Cells. <i>International Journal of Molecular Sciences</i> , 2015, 16, 6677-6693.	4.1	150
7	A splicing switch from ketohexokinase-C to ketohexokinase-A drives hepatocellular carcinoma formation. <i>Nature Cell Biology</i> , 2016, 18, 561-571.	10.3	143
8	PKM2 dephosphorylation by Cdc25A promotes the Warburg effect and tumorigenesis. <i>Nature Communications</i> , 2016, 7, 12431.	12.8	131
9	Lactate-Modulated Immunosuppression of Myeloid-Derived Suppressor Cells Contributes to the Radioresistance of Pancreatic Cancer. <i>Cancer Immunology Research</i> , 2020, 8, 1440-1451.	3.4	112
10	Single-cell analysis of pancreatic ductal adenocarcinoma identifies a novel fibroblast subtype associated with poor prognosis but better immunotherapy response. <i>Cell Discovery</i> , 2021, 7, 36.	6.7	109
11	MST1 Suppresses Pancreatic Cancer Progression via ROS-Induced Pyroptosis. <i>Molecular Cancer Research</i> , 2019, 17, 1316-1325.	3.4	88
12	Biomarkers for gastric cancer: Progression in early diagnosis and prognosis (Review). <i>Oncology Letters</i> , 2015, 9, 1502-1508.	1.8	87
13	A novel feedback loop between high MALAT-1 and low miR-200c-3p promotes cell migration and invasion in pancreatic ductal adenocarcinoma and is predictive of poor prognosis. <i>BMC Cancer</i> , 2018, 18, 1032.	2.6	44
14	Tumor-associated macrophages promote PD-L1 expression in tumor cells by regulating PKM2 nuclear translocation in pancreatic ductal adenocarcinoma. <i>Oncogene</i> , 2022, 41, 865-877.	5.9	42
15	Pretreatment C-reactive protein to albumin ratio for predicting overall survival in advanced pancreatic cancer patients. <i>Scientific Reports</i> , 2017, 7, 2993.	3.3	40
16	Activation of ClC-3 chloride channel by 17 β -estradiol relies on the estrogen receptor α expression in breast cancer. <i>Journal of Cellular Physiology</i> , 2018, 233, 1071-1081.	4.1	38
17	Histone deacetylase 3 promotes pancreatic cancer cell proliferation, invasion and increases drug-resistance through histone modification of P27, P53 and Bax. <i>International Journal of Oncology</i> , 2014, 45, 1523-1530.	3.3	37
18	The Major Cholesterol Metabolite Cholestane-3 β ,5 α ,6 β -Triol Functions as an Endogenous Neuroprotectant. <i>Journal of Neuroscience</i> , 2014, 34, 11426-11438.	3.6	36

#	ARTICLE	IF	CITATIONS
19	High co-expression of Sp1 and HER-2 is correlated with poor prognosis of gastric cancer patients. <i>Surgical Oncology</i> , 2015, 24, 220-225.	1.6	34
20	Patients with hepatic oligometastatic pancreatic body/tail ductal adenocarcinoma may benefit from synchronous resection. <i>Hpb</i> , 2020, 22, 91-101.	0.3	32
21	Prognostic value and clinicopathological features of PD-1/PD-L1 expression with mismatch repair status and desmoplastic stroma in Chinese patients with pancreatic cancer. <i>Oncotarget</i> , 2017, 8, 9354-9365.	1.8	32
22	The Joint Effects of Lifestyle Factors and Comorbidities on the Risk of Colorectal Cancer: A Large Chinese Retrospective Case-Control Study. <i>PLoS ONE</i> , 2015, 10, e0143696.	2.5	29
23	FOXM1-LDHA signaling promoted gastric cancer glycolytic phenotype and progression. <i>International Journal of Clinical and Experimental Pathology</i> , 2015, 8, 6756-63.	0.5	29
24	Characterization of the genomic landscape in large-scale Chinese patients with pancreatic cancer. <i>EBioMedicine</i> , 2022, 77, 103897.	6.1	29
25	Integrated genomic and transcriptomic analysis reveals unique characteristics of hepatic metastases and pro-metastatic role of complement C1q in pancreatic ductal adenocarcinoma. <i>Genome Biology</i> , 2021, 22, 4.	8.8	28
26	Sp1 and COX2 expression is positively correlated with a poor prognosis in pancreatic ductal adenocarcinoma. <i>Oncotarget</i> , 2016, 7, 28207-28217.	1.8	22
27	CHPF promotes gastric cancer tumorigenesis through the activation of E2F1. <i>Cell Death and Disease</i> , 2021, 12, 876.	6.3	21
28	FoxO1-negative cells are cancer stem-like cells in pancreatic ductal adenocarcinoma. <i>Scientific Reports</i> , 2015, 5, 10081.	3.3	20
29	Emodin suppresses the nasopharyngeal carcinoma cells by targeting the chloride channels. <i>Biomedicine and Pharmacotherapy</i> , 2017, 90, 615-625.	5.6	20
30	Aberrant expression of nuclear HDAC3 and cytoplasmic CDH1 predict a poor prognosis for patients with pancreatic cancer. <i>Oncotarget</i> , 2016, 7, 16505-16516.	1.8	20
31	Coordinated silencing of the Sp1-mediated long noncoding RNA MEG3 by EZH2 and HDAC3 as a prognostic factor in pancreatic ductal adenocarcinoma. <i>Cancer Biology and Medicine</i> , 2020, 17, 953-969.	3.0	19
32	First-line pembrolizumab plus chemotherapy versus chemotherapy in patients with advanced esophageal cancer: Chinese subgroup analysis of KEYNOTE-590. <i>Journal of Clinical Oncology</i> , 2021, 39, 4049-4049.	1.6	19
33	Elevated JMJD1A is a novel predictor for prognosis and a potential therapeutic target for gastric cancer. <i>International Journal of Clinical and Experimental Pathology</i> , 2015, 8, 11092-9.	0.5	19
34	Caveolin-2 is regulated by BRD4 and contributes to cell growth in pancreatic cancer. <i>Cancer Cell International</i> , 2020, 20, 55.	4.1	18
35	Suppression of epithelial-mesenchymal transition in hepatocellular carcinoma cells by KrÄppel-like factor 4. <i>Oncotarget</i> , 2016, 7, 29749-29760.	1.8	17
36	Antitumor effects of disulfiram/copper complex in the poorly-differentiated nasopharyngeal carcinoma cells via activating ClC-3 chloride channel. <i>Biomedicine and Pharmacotherapy</i> , 2019, 120, 109529.	5.6	16

#	ARTICLE	IF	CITATIONS
37	Application of next-generation sequencing technology to precision medicine in cancer: joint consensus of the Tumor Biomarker Committee of the Chinese Society of Clinical Oncology. <i>Cancer Biology and Medicine</i> , 2019, 16, 189.	3.0	16
38	Lysine demethylase 2 (KDM2B) regulates hippo pathway via MOB1 to promote pancreatic ductal adenocarcinoma (PDAC) progression. <i>Journal of Experimental and Clinical Cancer Research</i> , 2020, 39, 13.	8.6	16
39	Nitric Oxide and Pancreatic Cancer Pathogenesis, Prevention, and Treatment. <i>Current Pharmaceutical Design</i> , 2010, 16, 421-427.	1.9	14
40	Opening of the CLC ϵ 3 chloride channel induced by dihydroartemisinin contributed to early apoptotic events in human poorly differentiated nasopharyngeal carcinoma cells. <i>Journal of Cellular Biochemistry</i> , 2018, 119, 9560-9572.	2.6	14
41	A Survival Model in Locally Advanced and Metastatic Pancreatic Ductal Adenocarcinoma. <i>Journal of Cancer</i> , 2018, 9, 1301-1307.	2.5	12
42	Efficacy and safety of weekly nab-paclitaxel plus gemcitabine in Chinese patients with metastatic adenocarcinoma of the pancreas: a phase II study. <i>BMC Cancer</i> , 2017, 17, 885.	2.6	11
43	Quality-adjusted time without symptoms or toxicity (Q-TWiST) of patients with metastatic colorectal cancer (mCRC) treated with fruquintinib in a phase II clinical trial.. <i>Journal of Clinical Oncology</i> , 2018, 36, 765-765.	1.6	9
44	Patient-derived xenografts: a valuable platform for clinical and preclinical research in pancreatic cancer. <i>Chinese Clinical Oncology</i> , 2019, 8, 17-17.	1.2	8
45	JQ1 effectively inhibits vasculogenic mimicry of pancreatic ductal adenocarcinoma cells via the ERK1/2-MMP-2/9 signaling pathway both in vitro and in vivo. <i>American Journal of Translational Research (discontinued)</i> , 2019, 11, 1030-1039.	0.0	7
46	CMAB009 plus irinotecan versus irinotecan only as second line treatment after fluoropyrimidine and oxaliplatin failure in KRAS wild-type metastatic colorectal cancer patients: promising findings from a prospective, open-label, randomized, phase III trial. <i>Cancer Communications</i> , 2019, 39, 1-13.	9.2	6
47	RNA-binding protein Musashi2 regulates Hippo signaling via SAV1 and MOB1 in pancreatic cancer. <i>Medical Oncology</i> , 2020, 37, 84.	2.5	6
48	CSE1L, as a novel prognostic marker, promotes pancreatic cancer proliferation by regulating the AKT/mTOR signaling pathway. <i>Journal of Cancer</i> , 2021, 12, 2797-2806.	2.5	6
49	Measurement of serum cystatin C, creatinine clearance and urea micro-albumin as renal function evaluation indicators in cancer patients during chemotherapy with platinum. <i>Chinese-German Journal of Clinical Oncology</i> , 2011, 10, 235-239.	0.1	5
50	Modified FOLFIRINOX versus gemcitabine plus oxaliplatin as first-line chemotherapy for patients with locally advanced or metastatic cholangiocarcinoma: a retrospective comparative study. <i>BMC Cancer</i> , 2021, 21, 818.	2.6	5
51	Efficacy and tolerability of bevacizumab (BEV) plus capecitabine and cisplatin (XP) in Chinese patients (pts) with locally advanced or metastatic gastric/gastroesophageal junction cancer (AGC): Results from the AVATAR study.. <i>Journal of Clinical Oncology</i> , 2012, 30, 73-73.	1.6	5
52	Characterization of DNA damage response deficiency in pancreatic cancer patients from China. <i>Cancer Communications</i> , 2022, 42, 70-74.	9.2	5
53	Association of a novel point mutation in MSH2 gene with familial multiple primary cancers. <i>Journal of Hematology and Oncology</i> , 2017, 10, 158.	17.0	4
54	Efficacy of olanzapine for quality of life improvement among patients with malignant tumor: A systematic review. <i>Cancer Reports</i> , 2019, 2, e1167.	1.4	4

#	ARTICLE	IF	CITATIONS
55	Cost-effectiveness analysis of nab-paclitaxel plus gemcitabine versus folfinirox in the treatment of metastatic pancreatic cancer in china. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2020, 21, 1-7.	1.4	4
56	Vimentin-Rab7a Pathway Mediates the Migration of MSCs and Lead to Therapeutic Effects on ARDS. <i>Stem Cells International</i> , 2021, 2021, 1-12.	2.5	4
57	Research and clinical applications of molecular biomarkers in gastrointestinal carcinoma (Review). <i>Biomedical Reports</i> , 2013, 1, 819-827.	2.0	3
58	Synergistic blocking of RAS downstream signaling and epigenetic pathway in KRAS mutant pancreatic cancer. <i>Aging</i> , 2022, 14, 3597-3606.	3.1	3
59	Correlative analysis of plasma SN-38 levels and DPD activity with outcomes of FOLFIRI regimen for metastatic colorectal cancer with UGT1A1 *28 and *6 wild type and its implication for individualized chemotherapy. <i>Cancer Biology and Therapy</i> , 2017, 18, 186-193.	3.4	2
60	A multicenter, phase II study of trastuzumab plus capecitabine and oxaliplatin (XELOX) as first-line chemotherapy for HER2-positive advanced gastric cancer: Update results of efficacy and toxicity.. <i>Journal of Clinical Oncology</i> , 2014, 32, 102-102.	1.6	2
61	An open-label, randomized, multicenter, phase III study of S-1 and cisplatin versus docetaxel and cisplatin in patients with untreated advanced non-small-cell lung cancer.. <i>Journal of Clinical Oncology</i> , 2015, 33, 8039-8039.	1.6	2
62	A phase II study of Chinese patients (pts) treated with nab-paclitaxel (nab-P) plus gemcitabine (Gem) for metastatic pancreatic cancer (MPC).. <i>Journal of Clinical Oncology</i> , 2016, 34, 327-327.	1.6	2
63	Different properties between spontaneous and volume-activated chloride currents in human nasopharyngeal carcinoma and its normal counterpart cells. <i>Cell Biochemistry and Function</i> , 2019, 37, 486-493.	2.9	1
64	Fatal interstitial lung disease associated with a series of tyrosine kinase inhibitors treatment in a non-small cell lung cancer patient: a case report. <i>Translational Cancer Research</i> , 2020, 9, 3762-3765.	1.0	1
65	A narrative review of Safety management of 1 L platinum-based chemotherapy and maintenance olaparib in BRCA mutated advanced pancreatic cancer. <i>Translational Cancer Research</i> , 2021, 10, 2488-2495.	1.0	1
66	Effects of regorafenib therapy on health-related quality of life (HRQoL) in patients with metastatic colorectal cancer (mCRC) in the phase III CONCUR trial.. <i>Journal of Clinical Oncology</i> , 2015, 33, 697-697.	1.6	1
67	A phase I study of the safety and activity of K-001 in patients with advanced pancreatic ductal adenocarcinoma. <i>BMC Cancer</i> , 2021, 21, 672.	2.6	0
68	Use of plasma level of 5-fluorouracil to predict the efficacy in patients with advanced gastric cancer receiving first-line capecitabine plus cisplatin.. <i>Journal of Clinical Oncology</i> , 2012, 30, e14508-e14508.	1.6	0
69	Prognosis significance of HER2/neu overexpression and amplification in patients with curatively resected gastric cancer.. <i>Journal of Clinical Oncology</i> , 2012, 30, e14539-e14539.	1.6	0
70	Lymphocyte-to-monocyte ratio for predicting gemcitabine containing chemotherapy outcomes in pancreatic cancer patients.. <i>Journal of Clinical Oncology</i> , 2016, 34, e15720-e15720.	1.6	0
71	Early presence of antiangiogenesis-related adverse events as a potential biomarker of antitumor efficacy in patients with metastatic gastric cancer treated with apatinib.. <i>Journal of Clinical Oncology</i> , 2017, 35, 4052-4052.	1.6	0
72	Clinical Features of Multiple Primary Malignant Tumors: A Retrospective Clinical Analysis of 213 Chinese Patients at Two Centers.. <i>Discovery Medicine</i> , 2021, 32, 65-78.	0.5	0